Long-acting injectable buprenorphine - 'best practice' opioid agonist therapy for Australian prisoners.

Abstract

Objective: To consider opioid agonist therapy in prisons.

Conclusions: Given the substantial risks of substance misuse by prisoners, long-acting injectable buprenorphine should be adopted as 'best practice' treatment in Australian prison populations.